Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CMPS 
Compass Pathways Plc (CMPS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: CMPS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $14.9
1 Year Target Price $14.9
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -68.93% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 411.59M USD | Price to earnings Ratio - | 1Y Target Price 14.9 |
Price to earnings Ratio - | 1Y Target Price 14.9 | ||
Volume (30-day avg) 11 | Beta 2.17 | 52 Weeks Range 2.25 - 8.54 | Updated Date 08/13/2025 |
52 Weeks Range 2.25 - 8.54 | Updated Date 08/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.81 |
Earnings Date
Report Date 2025-07-30 | When Before Market | Estimate -0.4228 | Actual -0.4114 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -35.36% | Return on Equity (TTM) -71.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 218279134 | Price to Sales(TTM) - |
Enterprise Value 218279134 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.51 | Shares Outstanding 95941296 | Shares Floating 68226711 |
Shares Outstanding 95941296 | Shares Floating 68226711 | ||
Percent Insiders 13.3 | Percent Institutions 54.48 |
Upturn AI SWOT
Compass Pathways Plc
Company Overview
History and Background
Compass Pathways Plc was founded in 2016 and is focused on developing psilocybin therapy for mental health disorders. It aims to accelerate patient access to evidence-based innovation in mental health.
Core Business Areas
- Drug Development: Compass Pathways focuses on developing and commercializing COMP360, a proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD) and other mental health conditions.
- Clinical Trials: The company conducts clinical trials to demonstrate the safety and efficacy of COMP360 psilocybin therapy, with ongoing Phase 3 trials for TRD.
- Mental Health Ecosystem: Compass Pathways seeks to build a comprehensive mental health ecosystem around psilocybin therapy, including therapist training and digital tools.
Leadership and Structure
The leadership team includes Lars Wilde as CEO and Guy Goodwin as Chief Medical Officer. The company has a board of directors with expertise in pharmaceuticals, biotechnology, and mental health.
Top Products and Market Share
Key Offerings
- COMP360: COMP360 is Compass Pathways' lead product, a proprietary formulation of synthetic psilocybin. Market share data is not yet available as the drug is still in clinical trials. Competitors are other companies developing psychedelic therapies such as Atai Life Sciences (ATAI) and GH Research (GHRS).
Market Dynamics
Industry Overview
The psychedelic medicine industry is emerging, driven by increasing awareness of mental health disorders and the limitations of existing treatments. It's characterized by intense research, regulatory hurdles, and evolving public perception.
Positioning
Compass Pathways is a leading company in the psychedelic medicine space, particularly focused on psilocybin therapy. Its competitive advantages include its advanced clinical trials, intellectual property, and established relationships with regulators and researchers.
Total Addressable Market (TAM)
The estimated TAM for treatment-resistant depression is significant, potentially reaching billions of dollars annually. Compass Pathways is positioning itself to capture a substantial portion of this market with COMP360, if approved.
Upturn SWOT Analysis
Strengths
- First-mover advantage in psilocybin therapy for TRD
- Strong intellectual property portfolio
- Advanced clinical trial progress (Phase 3)
- Experienced management team
Weaknesses
- Reliance on a single drug candidate (COMP360)
- High cash burn rate
- Regulatory uncertainty surrounding psychedelic medicine
- Limited revenue generation
Opportunities
- Expansion into other mental health indications
- Partnerships with healthcare providers and insurers
- Positive clinical trial results
- Favorable regulatory changes
Threats
- Clinical trial failures
- Regulatory delays or rejection
- Competition from other psychedelic medicine companies
- Negative public perception of psychedelics
Competitors and Market Share
Key Competitors
- ATAI
- GHRS
- MNMD
Competitive Landscape
Compass Pathways has a first-mover advantage in psilocybin therapy for TRD, but faces increasing competition from other companies developing psychedelic medicines. Its strengths include its advanced clinical trials and intellectual property, while its weaknesses include its reliance on a single drug candidate and regulatory uncertainty.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increasing R&D investment and operating losses.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approval of COMP360. Analyst estimates vary widely, reflecting the uncertainty surrounding the company's prospects.
Recent Initiatives: Recent initiatives include expanding Phase 3 clinical trials for TRD, exploring COMP360 for other mental health indications, and developing therapist training programs.
Summary
Compass Pathways is a pioneering company in psychedelic medicine, particularly psilocybin therapy for TRD. It has a first-mover advantage and advanced clinical trials, but faces regulatory uncertainty and competition. The company's success hinges on positive clinical trial results and regulatory approval of COMP360. Its high cash burn rate requires careful management, and it will need to strategically expand its pipeline to secure long-term growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Investor Presentations
- Press Releases
- Third-Party Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The data provided is based on publicly available information and may not be exhaustive. Investment decisions should be based on individual risk tolerance and thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Compass Pathways Plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-18 | CEO & Director Mr. Kabir Kumar Nath M.A., M.B.A. | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 166 | Website https://compasspathways.com |
Full time employees 166 | Website https://compasspathways.com | ||
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.